Characterization of the latent membrane protein 1 signaling complex of Epstein-Barr virus in the membrane of mammalian cells with bimolecular fluorescence complementation

Virology Journal

Volumn 8, Issue , 2011, Pages

  Talaty, Pooja ^a   Emery, Amanda ^a   Everly, David N ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

bimolecular fluorescence complementation; Epstein Barr Virus; latent membrane protein 1; TRAF2; TRAF3

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; RED FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; YELLOW FLUORESCENT PROTEIN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; CELL CULTURE; CELL STRAIN HEK293; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LIPID RAFT; MAMMAL CELL; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PHENOTYPE; PLASMID; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MEMBRANE; CHEMISTRY; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RAT; STAINING; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; MAMMALIA; RODENTIA;

ANIMALS; CELL LINE; CELL MEMBRANE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; MICROSCOPY, FLUORESCENCE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; RATS; STAINING AND LABELING; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 80052022463     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-414     Document Type: Article

References (59)

1. Epstein-Barr Virus. Rickinson AB, Kieff E, Fields Virology Philadelphia: Lippincott Williams and Wilkins, Knipe DM, Howley PM, Fifth 2007 II 2655 2700
2. Epstein-Barr Virus and Its Replication. Kieff ED, Rickinson AB, Fields Virology Philadelphia: Lippincott Williams and Wilkins, Knipe DM, Howley PM, 5 2007 II 2603 2654
3. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Kaye KM, Izumi KM, Kieff E, Proc Natl Acad Sci USA 1993 90 9150 9154 10.1073/pnas.90.19.9150 8415670 (Pubitemid 23306469)
4. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Baichwal VR, Sugden B, Oncogene 1988 2 461 467 2836780
5. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. Everly DN Jr, Mainou BA, Raab-Traub N, J Virol 2004 78 13470 13478 10.1128/JVI.78.24.13470-13478.2004 15564458 (Pubitemid 39612747)
6. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Mainou BA, Everly DN Jr, Raab-Traub N, Oncogene 2005 24 6917 6924 10.1038/sj.onc.1208846 16007144 (Pubitemid 41509414)
7. Unique signaling properties of CTAR1 in LMP1-mediated transformation. Mainou BA, Everly DN Jr, Raab-Traub N, J Virol 2007 81 9680 9692 10.1128/JVI.01001-07 17626074 (Pubitemid 350067673)
8. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. Moorthy RK, Thorley-Lawson DA, J Virol 1993 67 1638 1646 8382313 (Pubitemid 23067672)
9. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Wang D, Liebowitz D, Kieff E, Cell 1985 43 831 840 10.1016/0092-8674(85)90256-9 3000618
10. Epstein-Barr virus in the pathogenesis of NPC. Raab-Traub N, Semin Cancer Biol 2002 12 431 441 10.1016/S1044579X0200086X 12450729 (Pubitemid 35370756)
11. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, et al. N Engl J Med 1989 321 1080 1085 10.1056/NEJM198910193211604 2552313 (Pubitemid 19256661)
12. Epstein-Barr virus: 40 years on. Young LS, Rickinson AB, Nat Rev Cancer 2004 4 757 768 10.1038/nrc1452 15510157 (Pubitemid 39331148)
13. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS, Virology 2000 272 204 217 10.1006/viro.2000.0344 10873763 (Pubitemid 30429444)
14. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Eliopoulos AG, Young LS, Oncogene 1998 16 1731 1742 10.1038/sj.onc.1201694 9582021 (Pubitemid 28175054)
15. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Izumi KM, Kieff ED, Proc Natl Acad Sci USA 1997 94 12592 12597 10.1073/pnas.94.23.12592 9356494 (Pubitemid 27492573)
16. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. Miller WE, Mosialos G, Kieff E, Raab-Traub N, J Virol 1997 71 586 594 8985387 (Pubitemid 26412329)
17. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. Paine E, Scheinman RI, Baldwin AS Jr, Raab-Traub N, J Virol 1995 69 4572 4576 7769726
18. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Roberts ML, Cooper NR, Virology 1998 240 93 99 10.1006/viro.1997.8901 9448693 (Pubitemid 28394127)
19. LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM, Raab-Traub N, Oncogene 2006 25 288 297 16247482 (Pubitemid 43083690)
20. Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Ardila-Osorio H, Clausse B, Mishal Z, Wiels J, Tursz T, Busson P, Int J Cancer 1999 81 645 649 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0 10225457 (Pubitemid 29203065)
21. TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Ardila-Osorio H, Pioche-Durieu C, Puvion-Dutilleul F, Clausse B, Wiels J, Miller W, Raab-Traub N, Busson P, Int J Cancer 2005 113 267 275 10.1002/ijc.20503 15386359 (Pubitemid 39628317)
22. Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Yasui T, Luftig M, Soni V, Kieff E, Proc Natl Acad Sci USA 2004 101 278 283 10.1073/pnas. 2237224100 14695890 (Pubitemid 38084241)
23. High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. Clausse B, Fizazi K, Walczak V, Tetaud C, Wiels J, Tursz T, Busson P, Virology 1997 228 285 293 10.1006/viro.1996.8380 9123836 (Pubitemid 27238796)
24. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). Brown KD, Hostager BS, Bishop GA, J Exp Med 2001 193 943 954 10.1084/jem.193.8.943 11304555 (Pubitemid 32525867)
25. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Higuchi M, Izumi KM, Kieff E, Proc Natl Acad Sci USA 2001 98 4675 4680 10.1073/pnas.081075298 11296297 (Pubitemid 32295035)
26. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. Kaykas A, Worringer K, Sugden B, EMBO J 2001 20 2641 2654 10.1093/emboj/20.11.2641 11387199 (Pubitemid 32938549)
27. A membrane leucine heptad contributes to trafficking, signaling, and transformation by latent membrane protein 1. Lee J, Sugden B, J Virol 2007 81 9121 9130 10.1128/JVI.00136-07 17581993 (Pubitemid 47311455)
28. LMP-1's transmembrane domains encode multiple functions required for LMP-1's efficient signaling. Kaykas A, Worringer K, Sugden B, J Virol 2002 76 11551 11560 10.1128/JVI.76.22.11551-11560.2002 12388716 (Pubitemid 35231311)
29. LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB. Soni V, Yasui T, Cahir-McFarland E, Kieff E, J Virol 2006 80 10787 10793 10.1128/JVI.01214-06 16928765 (Pubitemid 44628924)
30. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G, Mol Cell Biol 1996 16 7098 7108 8943365 (Pubitemid 26389769)
31. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED, Mol Cell Biol 1999 19 5759 5767 10409763 (Pubitemid 29339931)
32. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Huye LE, Ning S, Kelliher M, Pagano JS, Mol Cell Biol 2007 27 2910 2918 10.1128/MCB.02256-06 17296724 (Pubitemid 46581306)
33. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS, Mol Cell Biol 2008 28 6536 6546 10.1128/MCB.00785-08 18710948
34. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E, Proc Natl Acad Sci USA 2008 105 18448 18453 10.1073/pnas.0809933105 19017798
35. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS, J Virol 2008 82 3654 3664 10.1128/JVI.01888-07 18199641 (Pubitemid 351429941)
36. The ID proteins contribute to the growth of rodent fibroblasts during LMP1-mediated transformation. Everly DN Jr, Mainou BA, Raab-Traub N, Virology 2008 376 258 269 10.1016/j.virol.2007.12.003 18456300
37. LMP1 strain variants: biological and molecular properties. Mainou BA, Raab-Traub N, J Virol 2006 80 6458 6468 10.1128/JVI.00135-06 16775333 (Pubitemid 43927448)
38. Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation. Everly DN Jr, Mainou BA, Raab-Traub N, J Virol 2009 83 12671 12679 10.1128/JVI.01422-09 19828622
39. EBV Latent Membrane Protein 1 (LMP1) activates EGFR, STAT3 and ERK through effects on PKC{delta}. Kung CP, Meckes DG Jr, Raab-Traub N, J Virol 2011
40. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. Kung CP, Raab-Traub N, J Virol 2008 82 5486 5493 10.1128/JVI.00125-08 18367518 (Pubitemid 351705255)
41. Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. Kung CP, Raab-Traub N, J Virol 2010 84 6605 6614 10.1128/JVI.00344-10 20410275
42. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes. Thornburg NJ, Raab-Traub N, J Virol 2007 81 12954 12961 10.1128/JVI.01601-07 17881446 (Pubitemid 350156933)
43. New methodologies for measuring protein interactions in vivo and in vitro. Piehler J, Curr Opin Struct Biol 2005 15 4 14 10.1016/j.sbi.2005.01.008 15718127 (Pubitemid 40249503)
44. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Kerppola TK, Nat Protoc 2006 1 1278 1286 10.1038/nprot.2006.201 17406412
45. Capturing protein interactions in the secretory pathway of living cells. Nyfeler B, Michnick SW, Hauri HP, Proc Natl Acad Sci USA 2005 102 6350 6355 10.1073/pnas.0501976102 15849265 (Pubitemid 40617446)
46. Mechanism of action of a novel latent membrane protein-1 dominant negative. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M, J Biol Chem 2001 276 1195 1203 10.1074/jbc.M005461200 11031256 (Pubitemid 32096546)
47. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Floettmann JE, Rowe M, Oncogene 1997 15 1851 1858 10.1038/sj.onc.1201359 9362452 (Pubitemid 27478628)
48. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E, Cell 1995 80 389 399 10.1016/0092-8674(95)90489-1 7859281
49. Direct activation of protein kinases by unanchored polyubiquitin chains. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ, Nature 2009 461 114 119 10.1038/nature08247 19675569
50. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK, Science 2009 325 1134 1138 10.1126/science.1175065 19713527
51. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E, Proc Natl Acad Sci USA 1984 81 7207 7211 10.1073/pnas.81.22.7207 6095274 (Pubitemid 15216726)
52. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. Schultheiss U, Puschner S, Kremmer E, Mak TW, Engelmann H, Hammerschmidt W, Kieser A, EMBO J 2001 20 5678 5691 10.1093/emboj/20.20.5678 11598011 (Pubitemid 33010045)
53. Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt. Remy I, Michnick SW, Mol Cell Biol 2004 24 1493 1504 10.1128/MCB.24.4.1493-1504.2004 14749367 (Pubitemid 38167073)
54. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB, Proc Natl Acad Sci USA 2006 103 15014 15019 10.1073/pnas. 0606917103 17018644 (Pubitemid 44583156)
55. ERM-mediated genetic screens in mammalian cells. Liu D, Songyang Z, Methods Enzymol 2008 446 409 419 18603136
56. Genetic screens in mammalian cells by enhanced retroviral mutagens. Liu D, Yang X, Yang D, Songyang Z, Oncogene 2000 19 5964 5972 10.1038/sj.onc.1203992 11146547 (Pubitemid 32039371)
57. Bimolecular fluorescence complementation (BiFC) analysis of protein interactions in Caenorhabditis elegans. Hiatt SM, Shyu YJ, Duren HM, Hu CD, Methods 2008 45 185 191 10.1016/j.ymeth.2008.06.003 18586101
58. Visualization of ternary complexes in living cells by using a BiFC-based FRET assay. Shyu YJ, Suarez CD, Hu CD, Nat Protoc 2008 3 1693 1702 10.1038/nprot.2008.157 18846096
59. Visualization of AP-1 NF-kappaB ternary complexes in living cells by using a BiFC-based FRET. Shyu YJ, Suarez CD, Hu CD, Proc Natl Acad Sci USA 2008 105 151 156 10.1073/pnas.0705181105 18172215